ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Esperion's LDL drug aces a third pivotal trial
fiercebiotech
May 29, 2018In its third pivotal trial readout this year, the 180-mg dose of Esperion's LDL cholesterol-lowering treatment, bempedoic acid, hit its primary endpoint in a trial of high-risk patients with atherosclerotic cardiovascular disease (ASCVD).
Pharma Sources Insight January 2025
